GlassScriptPhysician profile
Danielle R Geroski
NPI 1972087161
$1,970.60
in general payments reported to CMS, 2019-2025
29 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $217 · 2022: $375 · 2023: $844 · 2024: $112 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $340.82 | 2021-2024 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $209.55 | 2021-2023 | Trelegy Ellipta, Arexvy |
| Insmed, INC. | $183.35 | 2022-2023 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $149.17 | 2021-2023 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.48 | 2021-2023 | Ofev |
| Sumitomo Pharma America, INC. | $117.95 | 2025 | Gemtesa, Orgovyx |
| Teleflex LLC | $100.52 | 2025 | Barrigel, Urolift |
| Axsome Therapeutics, INC. | $84.78 | 2023 | Sunosi |
| United Therapeutics Corporation | $70.07 | 2022-2023 | Tyvaso |
| Olympus America INC. | $58.55 | 2025 | Itind System |
| Antares Pharma, INC. | $52.33 | 2025 | Xyosted |
| Harmony Biosciences LLC | $48.03 | 2023 | Wakix |
| Sunovion Pharmaceuticals INC. | $37.73 | 2021 | |
| Blue Earth Diagnostics | $35.02 | 2024 | |
| Urogen Pharma, INC. | $31.89 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $30.48 | 2025 | Adstiladrin |
| Genzyme Corporation | $29.51 | 2022-2023 | |
| Electromed, INC. | $29.50 | 2021-2024 | Smartvest |
| Mylan Specialty L.P. | $25.89 | 2021-2022 | |
| Baxter Healthcare | $25.01 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Grifols USA, LLC | $23.75 | 2023 | Prolastin-C Liquid |
| Immunitybio, INC. | $21.73 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.35 | 2021 | |
| Inogen, INC. | $18.04 | 2023 | Inogen |
| Laborie Medical Technologies Corp. | $17.76 | 2025 | |
| Philips North America LLC | $17.11 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.81 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.29 | 2023 | |
| Calyxo, INC. | $14.13 | 2025 | Cvac Aspiration System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Geroski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.